Article

Real-world data of eribulin in advanced and pretreated HER2-negative breast cancer in a Spanish comprehensive cancer center

2019-11-18

Abstract excerpt

<title>Abstract</title> <p>Background Eribulin improves survival in pre-treated HER2-negative advanced breast cancer (ABC). However, limited data exist on co-morbidities and central nervous system (CNS) efficacy. The purpose of this study was to review eribulin’s efficacy and safety in everyday clinical practice with special focus on age, body mass index (BMI) and central nervous system (CNS) activity.Methods An...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 3caa610b-21ec-5dc0-8112-b426a2a6ce69
DOI: 10.21203/rs.2.14722/v3

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Real-world data of eribulin in advanced and pretreated HER2-negative breast cancer in a Spanish comprehensive cancer centerDOI 10.21203/rs.2.14722/v3Read

The efficacy and safety of pyrotinib in treating HER2-positive metastatic breast cancer patients:A multi-center studySemantic proximity Read

Targeted therapies for ER+/HER2- metastatic breast cancerSemantic proximity Read

How I treat endocrine-dependent metastatic breast cancer.Semantic proximity Read

Tolerability of Eribulin and Correlation Between Polymorphisms and Neuropathy in an Unselected Population of Female Patients with Metastatic Breast Cancer: Results of The Multicenter, Single Arm, Phase IV PAINTER StudySemantic proximity Read

Real-World Treatment Patterns and Outcomes in Elderly Patients with Metastatic Breast Cancer: A Multi- institutional Retrospective Cohort StudySemantic proximity Read

The Value of Oral Selective Estrogen Receptor Degraders in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer after Progression on ≥ 1 Line of Endocrine Therapy: Systematic Review and Meta-analysisSemantic proximity Read

Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access programSemantic proximity Read

Evaluating the investigational drug landscape for ESR1-mutated, estrogen receptor-positive, HER2-negative metastatic breast cancer.Semantic proximity Read

Efficacy and Safety of the use of Pertuzumab in Metastatic Breast Cancer Patients in a Real-World Setting: Results from the SUPER-GONO (Gruppo Oncologico del Nord Ovest) StudySemantic proximity Read

ER degradation for ER+/HER2‒ advanced or metastatic breast cancer: a phase 1 trialSemantic proximity Read

Elacestrant Plus Alpelisib in an ESR1 and PIK3CA Co-mutated and Heavily Pretreated Metastatic Breast Cancer: The First Case for Combination Efficacy and SafetySemantic proximity Read

LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases.Semantic proximity Read